Early goal-directed therapy using a physiological holistic view: the ANDROMEDA-SHOCK-a randomized controlled trial

Area of Science:

• Critical Care Medicine
• Cardiovascular Physiology
• Resuscitation Science

Background:

• Septic shock is a life-threatening condition where early recognition and management of tissue hypoperfusion are crucial.
• Current lactate-targeted resuscitation guidelines have limitations, as non-hypoxic lactate sources can be misleading.
• Peripheral perfusion-targeted resuscitation offers real-time feedback, potentially enabling quicker treatment adjustments and avoiding fluid overload.

Purpose of the Study:

• To evaluate if peripheral perfusion-targeted resuscitation reduces 28-day mortality in septic shock patients compared to lactate-targeted resuscitation.
• To assess the impact of peripheral perfusion-targeted resuscitation on secondary outcomes including organ dysfunction and resource utilization.

Main Methods:

• The ANDROMEDA-SHOCK study is a randomized controlled trial involving 422 patients with septic shock diagnosed within 4 hours.
• Participants receive either peripheral perfusion-targeted resuscitation (monitoring capillary refill time) or lactate-targeted resuscitation over an 8-hour period.
• Both groups follow a sequential treatment protocol involving fluid administration, vasopressors, and inodilators as needed, with 28-day mortality as the primary outcome.

Main Results:

• This section is not available in the provided abstract.

Conclusions:

• Peripheral perfusion-targeted resuscitation, if proven effective, could simplify treatment algorithms by providing real-time physiological assessment.
• This approach may prevent over-resuscitation and optimize the use of intensive care unit resources.
• The study aims to establish a more physiologically sound and potentially safer resuscitation strategy for septic shock.